2024
Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Ryuk D, Pelissari D, Alves K, Oliveira P, Castro M, Cohen T, Sanchez M, Menzies N. Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records. BMC Infectious Diseases 2024, 24: 531. PMID: 38802744, PMCID: PMC11129366, DOI: 10.1186/s12879-024-09417-7.Peer-Reviewed Original ResearchConceptsTreatment outcomesFactors associated with unsuccessful treatment outcomesHigher risk of poor treatment outcomeTB treatmentRisk of poor treatment outcomesUnsuccessful treatmentEffectiveness of TB treatmentAssociated with unsuccessful treatmentUnsuccessful treatment outcomesTuberculosis treatment outcomesDrug-susceptible TBHealth system levelMultivariate logistic regression modelService-related factorsTB drug resistanceComorbid health conditionsHealth-related behaviorsCategorizing treatment outcomesPatient-level factorsClinical examination resultsNational Disease Notification SystemPoor treatment outcomesDisease notification systemHIV infectionLogistic regression models
2018
The impact of digital health technologies on tuberculosis treatment: a systematic review
Ngwatu B, Nsengiyumva N, Oxlade O, Mappin-Kasirer B, Nguyen N, Jaramillo E, Falzon D, Schwartzman K, Abubakar I, Alipanah N, Bastos M, Boccia D, Chin D, Cohen T, Davis J, Denkinger C, Falzon D, Fielding K, Fox G, Free C, Garfein R, Hayward A, Jaramillo E, Lester R, Lewis J, Mappin-Kasirer B, Marx F, Menzies D, Migliori G, Nahid P, Ngwatu B, Nsengiyumva N, Nguyen N, Oxlade O, Schwartzman K, Siddiqi K, Story A, Thomas B, Trajman A, Yassin M. The impact of digital health technologies on tuberculosis treatment: a systematic review. European Respiratory Journal 2018, 51: 1701596. PMID: 29326332, PMCID: PMC5764088, DOI: 10.1183/13993003.01596-2017.Peer-Reviewed Original ResearchConceptsVideo-observed therapyMedication monitorsStandard careObservational studyTreatment completion ratesTB treatment adherenceProbability of cureTreatment of personsPerson DOTActive tuberculosisTB careClinical outcomesTreatment adherenceTuberculosis treatmentPatient outcomesTreatment completionControl groupTreatment dosesSystematic reviewDigital health technologiesShort message serviceEffect estimatesTuberculosisDigital interventionsCare
2016
Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective
Kendall EA, Cohen T, Mitnick CD, Dowdy DW. Second line drug susceptibility testing to inform the treatment of rifampin-resistant tuberculosis: a quantitative perspective. International Journal Of Infectious Diseases 2016, 56: 185-189. PMID: 28007660, PMCID: PMC5576040, DOI: 10.1016/j.ijid.2016.12.010.Peer-Reviewed Original ResearchMeSH KeywordsAntitubercular AgentsDirectly Observed TherapyHumansMicrobial Sensitivity TestsMycobacterium tuberculosisPrevalenceRifampinTreatment OutcomeTuberculosis, Multidrug-ResistantConceptsSecond-line drug susceptibility testingRifampin-resistant tuberculosisDrug susceptibility testingSecond-line drug resistanceDrug resistanceSusceptibility testingHigh-burden settingsSecond-line drugsDrug-resistant tuberculosisEffective regimensTreatment failureTreatment outcomesSmall incremental costEpidemiologic benefitsResistance amplificationPatientsTuberculosisIncremental costMost settingsWidespread implementationSettingRegimensPrevalence
2011
Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009
Jenkins HE, Zignol M, Cohen T. Quantifying the Burden and Trends of Isoniazid Resistant Tuberculosis, 1994–2009. PLOS ONE 2011, 6: e22927. PMID: 21829557, PMCID: PMC3146514, DOI: 10.1371/journal.pone.0022927.Peer-Reviewed Original ResearchConceptsIsoniazid preventive therapyIncident TB casesTB casesHIV prevalence countriesHigh HIV prevalence countriesPrevalence countriesHigh HIV prevalence areasRetreatment TB casesHIV prevalence areasIsoniazid-resistant tuberculosisControl of tuberculosisEffect of INHObserved time trendsWorld Health OrganizationPreventive therapyResistant tuberculosisIncident casesTreatment successPrevalence areasIsoniazid resistanceMultidrug resistanceHealth OrganizationTuberculosisINHNational data